# Beyond Air, Inc.: financial statements, quarterly

XAIR · Nasdaq · CIK 1641631 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/xair.md) · [Financials](/companies/xair/financials.md) · [Filings](/companies/xair/filings.md) · [Insiders](/companies/xair/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xair/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.2](/filings/0001493152-24-044579.md) | [0.4](/filings/0001493152-25-005678.md) | [0.5 d](/filings/0001641172-25-015750.md) | [0.7](/filings/0001641172-25-023243.md) | [0.8](/filings/0001493152-25-021561.md) | [1.1](/filings/0001493152-26-006688.md) | [1.2 d](/filings/0001493152-26-030287.md) | [1.8](/filings/0001493152-26-037781.md) | [1.8](/filings/0001493152-25-021561.md) | [2.2](/filings/0001493152-26-006688.md) | [1.9 d](/filings/0001493152-26-030287.md) | [1.8](/filings/0001493152-26-037781.md) |
| Cost of revenue | $m | [0.4](/filings/0001493152-24-044579.md) | [0.7](/filings/0001493152-25-005678.md) | [1.0 d](/filings/0001641172-25-015750.md) | [1.0](/filings/0001641172-25-023243.md) | [1.9](/filings/0001493152-25-021561.md) | [1.3](/filings/0001493152-26-006688.md) | [1.2 d](/filings/0001493152-26-030287.md) | [1.6](/filings/0001493152-26-037781.md) | [2.1](/filings/0001493152-25-021561.md) | [1.9](/filings/0001493152-26-006688.md) | [1.8 d](/filings/0001493152-26-030287.md) | [1.5](/filings/0001493152-26-037781.md) |
| Gross profit | $m | [(0.2)](/filings/0001493152-24-044579.md) | [(0.4)](/filings/0001493152-25-005678.md) | [(0.5) d](/filings/0001641172-25-015750.md) | [(0.3)](/filings/0001641172-25-023243.md) | [(1.1)](/filings/0001493152-25-021561.md) | [(0.2)](/filings/0001493152-26-006688.md) | [(0.0) d](/filings/0001493152-26-030287.md) | [0.2](/filings/0001493152-26-037781.md) | [(0.3)](/filings/0001493152-25-021561.md) | [0.3](/filings/0001493152-26-006688.md) | [0.1 d](/filings/0001493152-26-030287.md) | [0.2](/filings/0001493152-26-037781.md) |
| Research and development | $m | [7.1](/filings/0001493152-24-044579.md) | [6.8](/filings/0001493152-25-005678.md) | [5.7 d](/filings/0001641172-25-015750.md) | [6.0](/filings/0001641172-25-023243.md) | [4.6](/filings/0001493152-25-021561.md) | [3.0](/filings/0001493152-26-006688.md) | [3.3 d](/filings/0001493152-26-030287.md) | [3.1](/filings/0001493152-26-037781.md) | [2.5](/filings/0001493152-25-021561.md) | [2.4](/filings/0001493152-26-006688.md) | [2.3 d](/filings/0001493152-26-030287.md) | [2.0](/filings/0001493152-26-037781.md) |
| Selling, general and administrative | $m | [10.2](/filings/0001493152-24-044579.md) | [9.8](/filings/0001493152-25-005678.md) | [6.4 d](/filings/0001641172-25-015750.md) | [7.2](/filings/0001641172-25-023243.md) | [7.2](/filings/0001493152-25-021561.md) | [7.7](/filings/0001493152-26-006688.md) | [3.9 d](/filings/0001493152-26-030287.md) | [4.7](/filings/0001493152-26-037781.md) | [4.9](/filings/0001493152-25-021561.md) | [4.5](/filings/0001493152-26-006688.md) | [5.0 d](/filings/0001493152-26-030287.md) | [4.9](/filings/0001493152-26-037781.md) |
| Operating income | $m | [(17.5)](/filings/0001493152-24-044579.md) | [(17.0)](/filings/0001493152-25-005678.md) | [(12.6) d](/filings/0001641172-25-015750.md) | [(13.6)](/filings/0001641172-25-023243.md) | [(12.8)](/filings/0001493152-25-021561.md) | [(11.0)](/filings/0001493152-26-006688.md) | [(7.2) d](/filings/0001493152-26-030287.md) | [(7.6)](/filings/0001493152-26-037781.md) | [(7.7)](/filings/0001493152-25-021561.md) | [(6.6)](/filings/0001493152-26-006688.md) | [(7.2) d](/filings/0001493152-26-030287.md) | [(6.6)](/filings/0001493152-26-037781.md) |
| Interest expense | $m | [0.9](/filings/0001493152-23-040626.md) | [0.9](/filings/0001493152-24-005930.md) | [0.9 d](/filings/0001493152-24-025000.md) | [1.0](/filings/0001641172-25-023243.md) | [0.9](/filings/0001493152-25-021561.md) | [0.5](/filings/0001493152-26-006688.md) | [0.6 d](/filings/0001493152-26-030287.md) | [0.5](/filings/0001493152-26-037781.md) | [0.6](/filings/0001493152-25-021561.md) | [1.1](/filings/0001493152-26-006688.md) | [1.2 d](/filings/0001493152-26-030287.md) | [1.5](/filings/0001493152-26-037781.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(16.2)](/filings/0001493152-24-044579.md) | [(16.2)](/filings/0001493152-25-005678.md) | [(13.7) d](/filings/0001641172-25-015750.md) | [(12.2)](/filings/0001641172-25-023243.md) | [(13.4)](/filings/0001493152-25-021561.md) | [(13.0)](/filings/0001493152-26-006688.md) | [(8.0) d](/filings/0001493152-26-030287.md) | [(7.7)](/filings/0001493152-26-037781.md) | [(7.9)](/filings/0001493152-25-021561.md) | [(7.3)](/filings/0001493152-26-006688.md) | [(10.3) d](/filings/0001493152-26-030287.md) | [(7.9)](/filings/0001493152-26-037781.md) |
| Diluted EPS | $ per share | [(0.51)](/filings/0001493152-24-044579.md) | [(0.50)](/filings/0001493152-25-005678.md) | not reported | [(5.32)](/filings/0001641172-25-023243.md) | [(5.67)](/filings/0001493152-25-021561.md) | [(2.96)](/filings/0001493152-26-006688.md) | not reported | [(30.67)](/filings/0001493152-26-037781.md) | [(1.25)](/filings/0001493152-25-021561.md) | [(0.85)](/filings/0001493152-26-006688.md) | not reported | [(11.00)](/filings/0001493152-26-037781.md) |
| Basic EPS | $ per share | [(0.51)](/filings/0001493152-24-044579.md) | [(0.50)](/filings/0001493152-25-005678.md) | not reported | [(5.32)](/filings/0001641172-25-023243.md) | [(5.67)](/filings/0001493152-25-021561.md) | [(2.96)](/filings/0001493152-26-006688.md) | not reported | [(30.67)](/filings/0001493152-26-037781.md) | [(1.25)](/filings/0001493152-25-021561.md) | [(0.85)](/filings/0001493152-26-006688.md) | not reported | [(11.00)](/filings/0001493152-26-037781.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [13.2](/filings/0001493152-23-040626.md) | [8.0](/filings/0001493152-24-005930.md) | [11.4](/filings/0001641172-25-015750.md) | [4.2](/filings/0001493152-24-030444.md) | [28.4](/filings/0001493152-24-044579.md) | [4.6](/filings/0001493152-25-005678.md) | [4.7](/filings/0001493152-26-030287.md) | [5.0](/filings/0001641172-25-023243.md) | [9.7](/filings/0001493152-25-021561.md) | [6.6](/filings/0001493152-26-006688.md) | [6.7](/filings/0001493152-26-037781.md) | [5.5](/filings/0001493152-26-037781.md) |
| Current assets | $m | [47.1](/filings/0001493152-23-040626.md) | [39.4](/filings/0001493152-24-005930.md) | [43.9](/filings/0001641172-25-015750.md) | [30.9](/filings/0001493152-24-030444.md) | [38.0](/filings/0001493152-24-044579.md) | [19.3](/filings/0001493152-25-005678.md) | [16.0](/filings/0001493152-26-030287.md) | [15.0](/filings/0001641172-25-023243.md) | [18.6](/filings/0001493152-25-021561.md) | [25.6](/filings/0001493152-26-006688.md) | [24.8](/filings/0001493152-26-037781.md) | [22.8](/filings/0001493152-26-037781.md) |
| Total assets | $m | [58.0](/filings/0001493152-23-040626.md) | [51.9](/filings/0001493152-24-005930.md) | [57.0](/filings/0001641172-25-015750.md) | [46.5](/filings/0001493152-24-030444.md) | [53.0](/filings/0001493152-24-044579.md) | [34.1](/filings/0001493152-25-005678.md) | [30.1](/filings/0001493152-26-030287.md) | [28.1](/filings/0001641172-25-023243.md) | [31.0](/filings/0001493152-25-021561.md) | [36.8](/filings/0001493152-26-006688.md) | [35.4](/filings/0001493152-26-037781.md) | [32.9](/filings/0001493152-26-037781.md) |
| Current liabilities | $m | [12.5](/filings/0001493152-23-040626.md) | [11.6](/filings/0001493152-24-005930.md) | [11.6](/filings/0001641172-25-015750.md) | [11.8](/filings/0001493152-24-030444.md) | [6.6](/filings/0001493152-24-044579.md) | [5.4](/filings/0001493152-25-005678.md) | [5.0](/filings/0001493152-26-030287.md) | [4.6](/filings/0001641172-25-023243.md) | [4.4](/filings/0001493152-25-021561.md) | [5.0](/filings/0001493152-26-006688.md) | [6.5](/filings/0001493152-26-037781.md) | [6.9](/filings/0001493152-26-037781.md) |
| Total liabilities | $m | [29.2](/filings/0001493152-23-040626.md) | [28.4](/filings/0001493152-24-005930.md) | [29.8](/filings/0001641172-25-015750.md) | [28.8](/filings/0001493152-24-030444.md) | [23.7](/filings/0001493152-24-044579.md) | [15.8](/filings/0001493152-25-005678.md) | [15.7](/filings/0001493152-26-030287.md) | [17.7](/filings/0001641172-25-023243.md) | [17.9](/filings/0001493152-25-021561.md) | [28.5](/filings/0001493152-26-006688.md) | [29.2](/filings/0001493152-26-037781.md) | [30.1](/filings/0001493152-26-037781.md) |
| Long-term debt | $m | [17.5](/filings/0001493152-23-040626.md) | [17.5](/filings/0001493152-24-005930.md) | [17.5](/filings/0001493152-24-025000.md) | [17.5](/filings/0001493152-24-030444.md) | [12.5](/filings/0001493152-24-044579.md) | [11.8](/filings/0001493152-25-005678.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [25.7](/filings/0001493152-23-040626.md) | [20.8](/filings/0001493152-24-005930.md) | [25.0](/filings/0001641172-25-015750.md) | [16.1](/filings/0001493152-24-030444.md) | [28.1](/filings/0001493152-24-044579.md) | [17.6](/filings/0001493152-25-005678.md) | [13.6](/filings/0001493152-26-030287.md) | [9.9](/filings/0001641172-25-023243.md) | [12.7](/filings/0001493152-25-021561.md) | [8.1](/filings/0001493152-26-006688.md) | [6.1](/filings/0001493152-26-037781.md) | [2.0](/filings/0001493152-26-037781.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(14.3) d](/filings/0001493152-24-044579.md) | [(13.8) d](/filings/0001493152-25-005678.md) | [(10.7) d](/filings/0001641172-25-015750.md) | [(10.2)](/filings/0001641172-25-023243.md) | [(13.3) d](/filings/0001493152-25-021561.md) | [(7.7) d](/filings/0001493152-26-006688.md) | [(7.0) d](/filings/0001493152-26-030287.md) | [(4.5)](/filings/0001493152-26-037781.md) | [(4.5) d](/filings/0001493152-25-021561.md) | [(4.2) d](/filings/0001493152-26-006688.md) | [(4.9) d](/filings/0001493152-26-030287.md) | [(4.9)](/filings/0001493152-26-037781.md) |
| Capital expenditure | $m | [1.7 d](/filings/0001493152-24-044579.md) | [1.3 d](/filings/0001493152-25-005678.md) | [1.9 d](/filings/0001641172-25-015750.md) | [2.7](/filings/0001641172-25-023243.md) | [1.2 d](/filings/0001493152-25-021561.md) | [0.5 d](/filings/0001493152-26-006688.md) | [1.5 d](/filings/0001493152-26-030287.md) | [0.2](/filings/0001493152-26-037781.md) | [0.2 d](/filings/0001493152-25-021561.md) | [0.0 d](/filings/0001493152-26-006688.md) | [0.5 d](/filings/0001493152-26-030287.md) | [0.2](/filings/0001493152-26-037781.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [29.9](/filings/0001493152-23-040626.md) | [29.9](/filings/0001493152-24-005930.md) | [31.4](/filings/0001493152-24-030444.md) | [31.8](/filings/0001493152-24-044579.md) | [32.5](/filings/0001493152-25-005678.md) | [2.3](/filings/0001641172-25-023243.md) | [2.4](/filings/0001493152-25-021561.md) | [4.4](/filings/0001493152-26-006688.md) | [0.3](/filings/0001493152-26-037781.md) | [6.4](/filings/0001493152-25-021561.md) | [8.6](/filings/0001493152-26-006688.md) | [0.7](/filings/0001493152-26-037781.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 957,631 at 2026-08-12, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037781.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.